Vondran Maximilian, Abt Bernd, Nef Holger, Rastan Ardawan J
Department of Cardiac and Thoracic Vascular Surgery, University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany.
Department of Cardiac and Vascular Surgery, Herz-Kreislauf-Zentrum, Rotenburg an der Fulda, Germany.
Thorac Cardiovasc Surg Rep. 2021 Jan;10(1):e1-e5. doi: 10.1055/s-0040-1721483. Epub 2021 Jan 19.
Transcatheter aortic valve-in-valve implantation (VIV) is increasingly being used to successfully treat degenerated surgical aortic valve bioprostheses (SAVs). The new self-expanding transcatheter heart valve Allegra, from New Valve Technology with its special implantation mechanism, has proven its safety and feasibility for patients with degenerated SAVs, but it has never been used in the latest-generation sutureless SAV. To the best of our knowledge, this is the first description of the successful VIV of the Allegra prosthesis into a degenerated sutureless SAV, and the procedure yielded an excellent postinterventional hemodynamic results.
经导管主动脉瓣中瓣植入术（VIV）越来越多地被用于成功治疗退化的外科主动脉瓣生物假体（SAV）。新型自膨胀经导管心脏瓣膜Allegra由新瓣膜技术公司生产，具有特殊的植入机制，已证明其对退化SAV患者的安全性和可行性，但从未用于最新一代无缝合SAV。据我们所知，这是首次成功将Allegra假体VIV植入退化的无缝合SAV的描述，该手术产生了优异的介入后血流动力学结果。
